Skip to main content

Table 3 Summary of findings for medications to prevent superimposed preeclampsia

From: Medications for preventing hypertensive disorders in high-risk pregnant women: a systematic review and network meta-analysis

Patient or population: Pregnant women at any gestational age at high risk of developing hypertensive disorders in pregnancy

Settings: Hospital setting

Intervention: Antiplatelet agents, anticoagulants, antioxidants, calcium, nitric oxide, and their combinations

Comparator: Placebo or no treatment

Outcome: Superimposed preeclampsia

Total studies: 4 RCTs

Total participants: 6,342

Direct estimates

RR (95% CI)

Certainty of evidence

Indirect estimates

RR (95% CI)

Certainty of evidence

Network estimates

RR (95% CI)

[95% PrI]

Certainty of evidence

SUCRA

Commentsa

Antiplatelets (3 RCTs; 6,298 participants)

0.72 (0.46 to 1.14)

Lowb,c

Not estimable

0.72 (0.46 to 1.14)

[0.04 to 14.21]

Lowb,c

69.0%

There was no evidence of inconsistency for global inconsistency test (P = 0.165)

Antioxidants (1 RCT; 44 participants)

0.67 (0.12 to 3.61)

Very lowd,e

Not estimable

0.67 (0.12 to 3.61)

[< 0.001 to 37900]

Very lowd,e

60.6%

  1. GRADE Working Group grades of evidence
  2. High quality: Further research is very unlikely to change our confidence in the estimate of effect
  3. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
  4. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
  5. Very low quality: We are very uncertain about the estimate
  6. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
  7. CI Confidence interval, PrI Prediction interval, RR Relative risk
  8. aDias’s inconsistency tests of the node splitting not estimable
  9. bWe downgraded (1) level for serious limitations in study design due to most of the studies being at unclear risk of bias
  10. cWe downgraded (1) level for serious imprecision due to wide confidence interval
  11. dWe downgraded (2) level for very serious limitations in study design due to most of the studies being at high risk of bias
  12. eWe downgraded (2) level for very serious imprecision due to wide confidence interval and small number of events and sample size